PubRank

Yasuhiko Iida

Author PubWeight™ 27.75‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Development of a 111In-labeled peptide derivative targeting a chemokine receptor, CXCR4, for imaging tumors. Nucl Med Biol 2006 1.22
2 Temporal change in human nicotinic acetylcholine receptor after smoking cessation: 5IA SPECT study. J Nucl Med 2007 1.17
3 PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patients. Int J Clin Oncol 2006 1.16
4 Phosphorescent light-emitting iridium complexes serve as a hypoxia-sensing probe for tumor imaging in living animals. Cancer Res 2010 1.03
5 Present role and future prospects of positron emission tomography in clinical oncology. Cancer Sci 2006 0.97
6 Development of injectable O-15 oxygen and estimation of rat OEF. J Cereb Blood Flow Metab 2003 0.96
7 Current status of cancer therapy with radiolabeled monoclonal antibody. Ann Nucl Med 2005 0.94
8 Quantification of human nicotinic acetylcholine receptors with 123I-5IA SPECT. J Nucl Med 2004 0.93
9 Protective effect of zinc against ischemic neuronal injury in a middle cerebral artery occlusion model. J Pharmacol Sci 2006 0.90
10 Dual functional molecular imaging probe targeting CD20 with PET and optical imaging. Oncol Rep 2009 0.87
11 Lack of evidence for apoptosis as a cause of delayed onset paraplegia after spinal cord ischemia in rabbits. Anesth Analg 2003 0.87
12 Early diagnosis of recurrent hepatocellular carcinoma with 18F-FDG PET after radiofrequency ablation therapy. Oncol Rep 2007 0.85
13 Chemical design of a radiolabeled gelatinase inhibitor peptide for the imaging of gelatinase activity in tumors. Nucl Med Biol 2007 0.84
14 In vivo therapeutic effect of CDH3/P-cadherin-targeting radioimmunotherapy. Cancer Immunol Immunother 2012 0.83
15 Release of vesicular Zn2+ in a rat transient middle cerebral artery occlusion model. Brain Res Bull 2006 0.83
16 Radioimmunotherapy of solid tumors targeting a cell-surface protein, FZD10: therapeutic efficacy largely depends on radiosensitivity. Ann Nucl Med 2009 0.83
17 5-[123I]Iodo-A-85380: assessment of pharmacological safety, radiation dosimetry and SPECT imaging of brain nicotinic receptors in healthy human subjects. Ann Nucl Med 2004 0.82
18 Evaluation of radioiodinated 5-iodo-3-(2(S)-azetidinylmethoxy)pyridine as a ligand for SPECT investigations of brain nicotinic acetylcholine receptors. Ann Nucl Med 2002 0.82
19 5-Iodo-A-85380, a specific ligand for alpha 4 beta 2 nicotinic acetylcholine receptors, prevents glutamate neurotoxicity in rat cortical cultured neurons. Brain Res 2008 0.82
20 Changes in electroencephalographic bicoherence during sevoflurane anesthesia combined with intravenous fentanyl. Anesth Analg 2006 0.82
21 Evaluation of radioiodinated (R)-N-methyl-3-(2-iodophenoxy)-3-phenylpropanamine as a ligand for brain norepinephrine transporter imaging. Nucl Med Biol 2004 0.81
22 Generation of a transgenic animal model of hyperthyroid Graves' disease. Eur J Immunol 2003 0.81
23 Change of central cholinergic receptors following lesions of nucleus basalis magnocellularis in rats: search for an imaging index suitable for the early detection of Alzheimer's disease. Nucl Med Biol 2006 0.81
24 A new norepinephrine transporter imaging agent for cardiac sympathetic nervous function imaging: radioiodinated (R)-N-methyl-3-(2-iodophenoxy)-3-phenylpropanamine. Nucl Med Biol 2003 0.80
25 Norepinephrine transporter density as a causative factor in alterations in MIBG myocardial uptake in NIDDM model rats. Eur J Nucl Med Mol Imaging 2002 0.80
26 PET imaging of norepinephrine transporter-expressing tumors using 76Br-meta-bromobenzylguanidine. J Nucl Med 2010 0.80
27 In vivo measurement of presynaptic Zn2+ release during forebrain ischemia in rats. Biol Pharm Bull 2006 0.79
28 In vivo imaging of brain dopaminergic neurotransmission system in small animals with high-resolution single photon emission computed tomography. Anal Sci 2003 0.78
29 Age-related changes of myocardial norepinephrine transporter density in rats: implications for differential cardiac accumulation of MIBG in aging. Nucl Med Biol 2002 0.78
30 Diagnosis of maxillofacial tumor with L-3-[18f]-fluoro-alpha-methyltyrosine (FMT) PET: a comparative study with FDG-PET. Ann Nucl Med 2007 0.77
31 Brain extraction of 4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]pyridinium ion (HPP+), a neurotoxic metabolite of haloperidol: studies using [3H]HPP+. Jpn J Pharmacol 2002 0.77
32 Design, synthesis, and evaluation of [188Re]organorhenium-labeled antibody fragments with renal enzyme-cleavable linkage for low renal radioactivity levels. Bioconjug Chem 2007 0.76
33 Evaluation of (64)Cu-labeled DOTA-D-Phe(1)-Tyr (3)-octreotide ((64)Cu-DOTA-TOC) for imaging somatostatin receptor-expressing tumors. Ann Nucl Med 2009 0.75
34 [Biomedical imaging in pharmacology with nuclear medical imaging methodologies: positron emission tomography (PET) and single photon emission computed tomography (SPECT)]. Nihon Yakurigaku Zasshi 2003 0.75
35 Enhanced target-specific accumulation of radiolabeled antibodies by conjugating arginine-rich peptides as anchoring molecules. Bioconjug Chem 2010 0.75
36 Binding of 4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]pyridinium ion (HPP+), a metabolite of haloperidol, to synthetic melanin: implications for the dopaminergic neurotoxicity of HPP+. Neurotox Res 2004 0.75
37 Fractionated radioimmunotherapy with ⁹⁰Y-labeled fully human anti-CEA antibody. Cancer Biother Radiopharm 2013 0.75
38 Imaging P-glycoprotein function in rats using [(11)C]-N-desmethyl-loperamide. Ann Nucl Med 2013 0.75
39 In vivo relationship between thalamic nicotinic acetylcholine receptor occupancy rates and antiallodynic effects in a rat model of neuropathic pain: persistent agonist binding inhibits the expression of antiallodynic effects. Synapse 2011 0.75